Trial Profile
A Multi-Center, Phase Ib/II Study of Combination Treatment of APG-1252 With Paclitaxel in Patients With Relapsed/Refractory Small Cell Lung Cancer
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 01 Jun 2022
Price :
$35
*
At a glance
- Drugs Paclitaxel (Primary) ; Palcitoclax (Primary)
- Indications Small cell lung cancer
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors Ascentage Pharma
- 07 Jun 2022 Results (December 20, 2021, n=28 ) presented at the 58th Annual Meeting of the American Society of Clinical Oncology
- 07 Jun 2022 According to Ascentage Pharma media release, data from this study were presented at the 58th American Society of Clinical Oncology (ASCO) Annual Meeting.
- 18 May 2022 Status changed from active, no longer recruiting to discontinued due to sponsor decision.